Skip to main content
Uncategorized

Laura Herrero from IBUB is the only national researcher awarded with the ‘Rising Star Award’ by the EFSD

By 18 de October de 2012No Comments
< Back to news
The awarded researchers Laura Herrero, Amélie Bonnefond, Joline W. Beulens i Henrike Sell (left to right).
 18.10.2012

Laura Herrero from IBUB is the only national researcher awarded with the ‘Rising Star Award’ by the EFSD

Laura Herrero, member of the UB Institute of Biomedicine (IBUB) –based in the Barcelona Science Park– is the only national researcher awarded with the Rising Star Award by the European Foundation for the Study of Diabetes (EFSD) and the pharmaceutical Jansen. This award, the most important that the EASD confers on young European researchers who study diabetes, was also conferred on the following experts: Joline Beulens (Netherlands), Amélie Bonnefond (France) and Henrike Sell (Germany).


Laura Herrero is lecturer at the Department of Biochemistry and Molecular Biology in the UB Faculty of Pharmacy –affiliated center to the campus of international excellence Barcelona Knowledge Campus (BKC)–, expert from the Regulation of the Lipid Metabolism UB Group and member to the Biomedical Research Networking centre (CIBER) in Obesity and Nutrition Physiopathology (CIBERobn).

The Rising Star award was conferred for her project ‘Enhancing brown adipose tissue fat-burning power as a therapy against obesity-induced diabetes‘, which analyses how the excessive fat characteristic of obesity can be removed, in order to strengthen the action of the brown adipose tissue, the main organ in charge of the energy expenditure. The project also received one of the Lilly research fellowships in 2012.

The Rising Star awards were conferred on 2nd October during the 48th EASD Conference in Berlin. In this event, Laura Herrero gave a talk titled ‘Adipose tissue inflammation in obesity and lipodystrophy‘, centred on her research activity about the relation between obesity and the diabetes which does not answer to insulin and the new therapeutic treatments to fight these metabolic disorders.